[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338457-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338457-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","abemaciclib-and-letrozole-in-metastatic-male-breast-cancer-case-report","Abemaciclib and Letrozole in Metastatic Male Breast Cancer - Case Report","","Male breast cancer is a rare disease, representing about 1% of all breast cancers, and men currently lack randomized evidence for specific treatment strategies. This open-access case report describes an advanced metastatic male patient treated with letrozole combined with abemaciclib. The therapy was well tolerated without reported side effects. Follow-up CT demonstrated regression of the primary tumor mass, along with lymph node and soft-tissue metastases, supporting clinical effectiveness for future cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/abemaciclib-and-letrozole-in-metastatic-male-breast-cancer-case-report/338457/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/abemaciclib-and-letrozole-in-metastatic-male-breast-cancer-case-report/338457.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is treatment evidence limited for male breast cancer?","Question",{"text":63,"@type":64},"Male breast cancer is very rare (around 1% of all breast cancers), and randomized data supporting male-specific treatment modalities are lacking.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What treatment combination is reported in this case?",{"text":68,"@type":64},"The case report describes a male patient with advanced metastatic breast cancer treated with letrozole in combination with abemaciclib.",{"name":70,"@type":61,"acceptedAnswer":71},"How did the patient respond to the therapy?",{"text":72,"@type":64},"The therapy was well tolerated with no reported side effects, and follow-up CT showed regression of the primary tumor, lymph nodes, and soft-tissue metastases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338457,1790592154,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Cancer Reports  \nCASE REPORT  OPEN ACCESS   \nAbemaciclib and Letrozole in Metastatic Male  \nBreast Cancer  \nLeon Schönfeld1  | Christian Möhring1 | Rouven Strobel1 | Hanns Leonhard Kaatsch2 | Stephan Waldeck2 | Ulrike Wagner1  \n1Department for Internal Medicine, Bundeswehr Central Hospital, Koblenz, Germany | 2Department for Diagnostic and Interventional Radiology and  \nNeuroradiology, Bundeswehr Central Hospital, Koblenz, Germany Correspondence: Leon Schönfeld ([leon.schoenfeld@icloud.com](leon.schoenfeld@icloud.com))  \nReceived: 3 August 2024 | Revised: 16 October 2024 | Accepted: 23 October 2024  \nFunding: The authors received no specific funding for this work.  \nKeywords: abemaciclib | CDK4/6 inhibitor | male breast cancer | metastatic disease  \nABSTRACT  \nBackground: Male breast cancer is a very rare disease and only accounts for around 1% of all breast cancers. The treatment strategies are based on those used for breast cancer in women. So far, there is a lack of randomized data to support specific treatment modalities in men. To our knowledge, a therapeutic approach with a combination of letrozole and abemaciclib has not yet been described for a male patient with metastatic breast cancer.  \nCase Description: Here, we report a case of a male patient with advanced metastatic breast cancer treated with a combination of letrozole and abemaciclib. The therapy was well tolerated with no reported side effects. The follow-up CT showed regression of the primary tumor mass and the lymph nodes and soft tissue metastases.  \nConclusion: In summary, this case report clearly shows the effectiveness of the therapeutic approach and should be discussed for the treatment of future patients.  \n1 | Background  \nMale breast cancer (MBC) is avery rare condition, accounting for only about 1% of all breast cancers. Often, the diagnosis is made at an advanced stage, resulting in increased mortality [1] . The 5-and 10-year survival rates for MBC are reported to be 77% and 68%, respectively [2]. Risk factors for developing MBC include a shift in the androgen/estrogen ratio due to obesity, alcoholism, liver cirrhosis, and testicular dysfunction. Another risk factor is a positive family history, with first-degree relatives having a threefold increased risk for MBC. Genetic risk mutations are associated with homologous recombination deficiency. About 10% of patients have a BRCA-2 mutation [3, 4] . Clinically, the disease most commonly presents as tumor growth, nipple retraction, or secretion. The diagnosis is made a median of 6 months after the onset of symptoms. Due to the often delayed diagnosis, up to 31% of patients have local lymph node involvement at the time of  \ninitial diagnosis [3, 5]. The most common entity of MBC is invasive ductal carcinoma. Most carcinomas are hormone receptorpositive. HER2-neu positivity is seen in a few cases. The Ki67 labeling index, a proliferation marker, is described as having an activity of \u003C 20% in 75% of cases. The androgen receptor is positive in 96.9% of cases [6] . Prognostically, male patients show significantly higher mortality compared to female breast cancer patients (FBC). The 3-year mortality for male patients is 15% higher, and the 5-year mortality is 19% higher than for female patients [7] .  \nVarious therapeutic regimens exist for metastatic MBC, modeled after the treatment of female breast cancer, as prospective randomized studies on MBC are lacking. First-line therapy for metastatic, hormone receptor-positive carcinoma is recommended to be Tamoxifen. This therapy can be supplemented with anaromatase inhibitor and/or a gonadotropin-releasing hormone  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Cancer Reports published by Wiley Periodicals LLC.  \nCancer Reports, 2024; 7:e70054 1 of 5  \n[https://doi.org/10.1002/cnr2.7005","cbCainRSVQU3l06P","https://ap.wps.com/l/cbCainRSVQU3l06P","pdf",1432206,"English","# Background\n## Case description\n## Conclusion\n# Background\n## Disease overview and risk factors\n## Treatment approaches for metastatic male breast cancer\n# Case\n## Presentation and admission findings","[{\"question\":\"Why is treatment evidence limited for male breast cancer?\",\"answer\":\"Male breast cancer is very rare (around 1% of all breast cancers), and randomized data supporting male-specific treatment modalities are lacking.\"},{\"question\":\"What treatment combination is reported in this case?\",\"answer\":\"The case report describes a male patient with advanced metastatic breast cancer treated with letrozole in combination with abemaciclib.\"},{\"question\":\"How did the patient respond to the therapy?\",\"answer\":\"The therapy was well tolerated with no reported side effects, and follow-up CT showed regression of the primary tumor, lymph nodes, and soft-tissue metastases.\"}]","Abemaciclib and Letrozole in Metastatic Male Breast Cancer - Case Report | PDF",1790023709,13,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93a4e36e758de83b4165d496673a9963.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/185b7cbbe51d308d04146f778813b001.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b210a8b4ca44aaeac4161dd490e98ce7.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bfa02dc374a532bfd9f3d91432931b8.webp",980,1287]